TSE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis C$2.15 +0.04 (+1.90%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades About Medexus Pharmaceuticals Stock (TSE:MDP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MDP alerts:Sign Up Key Stats Today's RangeC$2.11▼C$2.1850-Day RangeC$1.96▼C$2.7352-Week RangeC$1.44▼C$3.16Volume19,005 shsAverage Volume41,582 shsMarket CapitalizationC$52.74 millionP/E Ratio43.00Dividend YieldN/APrice TargetC$5.25Consensus RatingBuy Company OverviewMedexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.Read More… New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Medexus Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks58th Percentile Overall ScoreMDP MarketRank™: Medexus Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingMedexus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMedexus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Medexus Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Medexus Pharmaceuticals is 43.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.33.Price to Earnings Ratio vs. SectorThe P/E ratio of Medexus Pharmaceuticals is 43.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 134.37.Price to Book Value per Share RatioMedexus Pharmaceuticals has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Medexus Pharmaceuticals' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MDP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedexus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMedexus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MDP. News and Social Media2.1 / 5News Sentiment-0.20 News SentimentMedexus Pharmaceuticals has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Medexus Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest1 people have searched for MDP on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Medexus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Medexus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$10,916.00 in company stock and sold C$0.00 in company stock.Percentage Held by InsidersOnly 9.14% of the stock of Medexus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 8.32% of the stock of Medexus Pharmaceuticals is held by institutions.Read more about Medexus Pharmaceuticals' insider trading history. Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDP Stock News HeadlinesBloom Burton Issues Pessimistic Outlook for TSE:MDP EarningsNovember 15, 2024 | americanbankingnews.comShould We Be Cautious About Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 7.0%?November 10, 2024 | finance.yahoo.comDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.November 21, 2024 | DTI (Ad)Medexus Pharmaceuticals Inc (TSX:MDP) Q2 2025: Everything You Need to Know Ahead of EarningsNovember 7, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc (TSX:MDP) Q2 2025 Earnings Report Preview: What To Look ForNovember 6, 2024 | finance.yahoo.comFDA extends review period for Medexus' treosulfan to 2025September 16, 2024 | msn.comSome May Be Optimistic About Medexus Pharmaceuticals' (TSE:MDP) EarningsAugust 20, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextAugust 10, 2024 | finance.yahoo.comSee More Headlines MDP Stock Analysis - Frequently Asked Questions How have MDP shares performed this year? Medexus Pharmaceuticals' stock was trading at C$2.47 at the start of the year. Since then, MDP shares have decreased by 13.0% and is now trading at C$2.15. View the best growth stocks for 2024 here. How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Medexus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS). Company Calendar Today11/20/2024Next Earnings (Estimated)2/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:MDP CUSIPN/A CIKN/A Webwww.medexus.com Phone877-633-3987FaxN/AEmployees98Year FoundedN/APrice Target and Rating Average Stock Price TargetC$5.25 High Stock Price TargetC$8.25 Low Stock Price TargetC$3.50 Potential Upside/Downside+144.2%Consensus RatingBuy Rating Score (0-4)3.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)C$0.05 Trailing P/E Ratio43.00 Forward P/E Ratio13.16 P/E GrowthN/ANet IncomeC$1.09 million Net Margins1.00% Pretax MarginN/A Return on Equity3.95% Return on Assets4.89% Debt Debt-to-Equity Ratio143.72 Current Ratio1.11 Quick RatioN/A Sales & Book Value Annual SalesC$108.78 million Price / Sales0.48 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.33 per share Price / Book1.62Miscellaneous Outstanding Shares24,530,000Free FloatN/AMarket CapC$52.74 million OptionableNot Optionable Beta1.96 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (TSE:MDP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.